Clinical trial
Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder
NCT00437099 · Hospital Universitari Vall d'Hebron Research Institute, Other · Unknown status
Key facts
| NCT number | NCT00437099 |
|---|---|
| Title | Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder |
| Official title | Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder: a Randomized, Double Blind Clinical Trial. |
| Lead sponsor | Hospital Universitari Vall d'Hebron Research Institute, Other |
| Status | Unknown status |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Borderline Personality Disorder. |
| Intervention type | Drug |
| Interventions | Omacor®, Placebo |
| Enrollment | 102 |
| Start date | Feb 1, 2009 |
| Primary completion | Feb 1, 2011 |
| Completion | Sep 1, 2011 |
| First posted | Feb 19, 2007 |
| Last update posted | May 27, 2010 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: